首页> 美国卫生研究院文献>BMJ Case Reports >Novel treatment (new drug/intervention; established drug/procedure in new situation): Repeated phlebotomies improve and stabilise renal function in cyanotic nephropathy
【2h】

Novel treatment (new drug/intervention; established drug/procedure in new situation): Repeated phlebotomies improve and stabilise renal function in cyanotic nephropathy

机译:新疗法(新药/干预;新情况下已确立的药物/程序):反复静脉切开术改善并稳定了紫otic性肾病的肾功能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patients over 10 years of age with cyanotic congenital heart disease (CCHD) risk developing significant glomerular proteinuria, a condition called cyanotic nephropathy. Even though the pathogenesis of glomerulopathy associated with CCHD is still unclear, a potential mechanism is hyperviscosity-induced decrease in peritubular capillary blood flow leading to an increase in glomerular capillary pressure, in turn resulting in proteinuria. Although angiotensin-converting enzyme (ACE) inhibitors have been traditionally used in the treatment of these patients with cyanotic nephropathy, they may, however, not be well tolerated. Here we present a case of an adult patient with CCHD who could not tolerate an ACE inhibitor but showed improvement and stabilisation of her renal function following treatment with repeated phlebotomies.
机译:患有发otic性先天性心脏病(CCHD)的10岁以上患者有发展为严重肾小球蛋白尿的风险,这种疾病称为发otic性肾病。尽管与CCHD相关的肾小球病的发病机制仍不清楚,但潜在的机制是高粘度诱导的肾小管周围毛细血管血流减少导致肾小球毛细血管压力增加,进而导致蛋白尿。尽管传统上已将血管紧张素转换酶(ACE)抑制剂用于治疗这些紫性肾病患者,但耐受性可能不佳。在这里,我们介绍了一名患有CCHD的成年患者,该患者不能耐受ACE抑制剂,但经过多次静脉切开术治疗后,肾功能得到改善和稳定。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号